← Back to patent-cliff list
Kanglaite
Tier C — Watch / tradeKanglaite
-
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BCL2, Apoptosis-mediating surface antigen FAS
Brand：Kanglaite
Indications (approved)：Non-small cell lung cancer, Liver cancer
Regional status
US
Discontinued
2011-11-01
EU
-
China
Approved
1997-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Kanglaite?
Approved indications include: Non-small cell lung cancer, Liver cancer.
When does the Kanglaite patent expire?
No public expiry year is available for Kanglaite yet; this page updates once verified.
How do I get a quote for Kanglaite intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27